Monosomy 6 in human cultured fibroblast-like cells permanently stimulated by fibroblast growth factor 1: evidence for selection.
The appearance of cells with monosomy 6 (mono6 cells) in cultures of human fibroblast-like cells during long-term stimulation with acidic fibroblast growth factor (FGF1) was confirmed in five of the six lines newly investigated. Aneugenic pretreatment at the start of the cultures accelerated the emergence of mono6 cells, as would be expected if selection, rather than induction, is the main mechanism involved. This could be confirmed by using an incidental rearrangement, der(8)t(6p;8p), that emerged in one of the lines by monitoring the proliferation of the mono6 cells (here monosomic for 6p22.1-->qter) in mixtures with normal cells. During growth in the presence of FGF1, the proportion of mono6 cells increased six fold, whereas in the absence of FGF1, it declined to background levels. Selection rather than induction of the mono6 cells is further supported by their clonal origin, as ascertained on the basis of X-inactivation patterns in three informative cases. In addition, colonies grown in the presence of FGF1 from single cells did not reveal higher proportions of mono6 cells by fluorescence in situ hybridization analysis than those grown without the growth factor. During permanent stimulation with FGF1, the growth of mono6 cells did not become dependent on FGF1, nor did these cells lose their responsiveness to FGF1. Although evidence in favor of selection of preexistent mono6 cells by FGF1 is provided in this study, the contribution of a primary inducing mechanism cannot be entirely excluded.
Kehrer-Sawatzki
H
H
Abteilung Humangenetik, Universität Ulm, Germany.
Röck
H
H
Götz
H
H
Siegel
A
A
Krone
W
W
D000328:Adult; D000483:Alleles; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002648:Child; D019457:Chromosome Breakage / Q000235:genetics; D002896:Chromosomes, Human, Pair 6 / Q000235:genetics*; D002999:Clone Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D004303:Dosage Compensation, Genetic; D005260:Female; D016220:Fibroblast Growth Factor 1; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D019656:Loss of Heterozygosity / Q000235:genetics; D008297:Male; D018895:Microsatellite Repeats / Q000235:genetics; D009006:Monosomy / Q000235:genetics*; D009630:Nondisjunction, Genetic; D011944:Receptors, Androgen / Q000235:genetics; D012641:Selection, Genetic; D013997:Time Factors
D011944:Receptors, Androgen; D016222:Fibroblast Growth Factor 2; D016220:Fibroblast Growth Factor 1